Journal
JOURNAL OF CANCER
Volume 12, Issue 9, Pages 2570-2581Publisher
IVYSPRING INT PUBL
DOI: 10.7150/jca.53134
Keywords
PIM2; oncogene; protein kinase; phosphorylation; inhibitors
Categories
Funding
- Innovation fund of National Natural Science Foundation of China [81972489]
- National Natural Science Foundation of Shandong Province [ZR2020YQ58]
Ask authors/readers for more resources
PIM2 kinase is a key oncogene in multiple cancers, promoting transcriptional activation of genes involved in cell survival, proliferation, and cell-cycle progression. Numerous tumorigenic signaling molecules have been identified as substrates for PIM2 kinase, leading to the development of various inhibitors. PIM2 is poised to become a therapeutic target in cancer treatment in the future.
PIM2 (proviral integration site for Moloney murine leukemia virus 2) kinase plays an important role as an oncogene in multiple cancers, such as leukemia, liver, lung, myeloma, prostate and breast cancers. PIM2 is largely expressed in both leukemia and solid tumors, and it promotes the transcriptional activation of genes involved in cell survival, cell proliferation, and cell-cycle progression. Many tumorigenic signaling molecules have been identified as substrates for PIM2 kinase, and a variety of inhibitors have been developed for its kinase activity, including SMI-4a, SMI-16a, SGI-1776, JP11646 and DHPCC-9. Here, we summarize the signaling pathways involved in PIM2 kinase regulation and PIM2 mechanisms in various neoplastic diseases. We also discuss the current status and future perspectives for the development of PIM2 kinase inhibitors to combat human cancer, and PIM2 will become a therapeutic target in cancers in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available